Cadila Pharmaceuticals on Tuesday said it has launched a drug under the brand name Belmore (Bempedoic acid) for the treatment of high LDL-cholesterol.
Bempedoic acid is a one-of-its-kind drug for the treatment of high LDL (low-density lipoprotein) cholesterol, also known as bad cholesterol which can lead to serious life-threatening heart complications due to blockage in blood vessels.
"Belmore (bempedoic acid) provides additional benefits to patients, and all pre-launch studies have established this advantage. Belmore is one more addition to our fast-growing portfolio of indigenous innovations," Cadila Pharmaceuticals CEO for Domestic Prescription Business Jawed Zia said in a statement.
As per published data, more than 30% of adults in urban areas and 20% in rural areas in the country are suffering from the heart ailment.
Statins are the group of drugs used to control LDL-cholesterol, but in more than 80% of the patients, these drugs either do not give optimum control or are not tolerated.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
